 [1m([0morchestrator-myocardial infarction-PIMOZIDE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes PIMOZIDE increase or decrease the risk of myocardial [0m
[34minfarction?[0m
 [1m([0morchestrator-myocardial infarction-PIMOZIDE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-myocardial infarction-PIMOZIDE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-myocardial infarction-PIMOZIDE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does PIMOZIDE increase or decrease the risk of myocardial infarction?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-myocardial infarction-PIMOZIDE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes PIMOZIDE increase or decrease the risk of myocardial [0m
[32minfarction?[0m
 [1m([0morchestrator-myocardial infarction-PIMOZIDE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-myocardial infarction-PIMOZIDE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-myocardial infarction-PIMOZIDE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes PIMOZIDE increase or decrease the risk of myocardial infarction?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does PIMOZIDE increase or decrease the risk of myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"PIMOZIDE"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: PIMOZIDE: precautions: The concentrations observed in poor CYP 2D6 metabolizers are similar to those seen with strong CYP 2D6 inhibitors such as paroxetine. The time to achieve steady state [0m
[31mPimozide concentrations is expected to be longer [0m[1;31m([0m[31mapproximately [0m[1;31m2[0m[31m weeks[0m[1;31m)[0m[31m in poor CYP 2D6 metabolizers because of the prolonged half-life. Alternative dosing strategies are recommended in patients who [0m
[31mare genetically poor CYP 2D6 metabolizers [0m[1;31m([0m[31msee DOSAGE and ADMINISTRATION [0m[1;31m)[0m[31m. Interaction with Food Patients should avoid grapefruit juice because it may inhibit the metabolism of pimozide by CYP 3A4. [0m
[31mCARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY Carcinogenicity studies were conducted in mice and rats. In mice, pimozide causes a dose-related increase in pituitary and mammary tumors. [0m
[31mPIMOZIDE: precautions: When mice were treated for up to [0m[1;31m18[0m[31m months with pimozide, pituitary gland changes developed in females only. These changes were characterized as hyperplasia at doses [0m
[31mapproximating the human dose and adenoma at doses about fifteen times the maximum recommended human dose on a mg per kg basis. The mechanism for the induction of pituitary tumors in mice is not known.[0m
[31mMammary gland tumors in female mice were also increased, but these tumors are expected in rodents treated with antipsychotic drugs which elevate prolactin levels. Chronic administration of an [0m
[31mantipsychotic also causes elevated prolactin levels in humans. Tissue culture experiments indicate that approximately one-third of human breast cancers are prolactin-dependent in vitro, a factor of [0m
[31mpotential importance if the prescription of these drugs is contemplated in a patient with a previously detected breast cancer. PIMOZIDE: precautions: Although disturbances such as galactorrhea, [0m
[31mamenorrhea, gynecomastia, and impotence have been reported with antipsychotic drugs, the clinical significance of elevated serum prolactin levels is unknown for most patients. Neither clinical studies[0m
[31mnor epidemiologic studies conducted to date have shown an association between chronic administration of these drugs and mammary tumorigenesis. The available evidence, however, is considered too [0m
[31mlimited to be conclusive at this time. In a [0m[1;31m24[0m[31m-month carcinogenicity study in rats, animals received up to [0m[1;31m50[0m[31m times the maximum recommended human dose. No increased incidence of overall tumors or [0m
[31mtumors at any site was observed in either sex. Because of the limited number of animals surviving this study, the meaning of these results is unclear. Pimozide did not have mutagenic activity in the [0m
[31mAmes test with four bacterial test strains, in the mouse dominant lethal test or in the micronucleus test in rats. PIMOZIDE: precautions: Reproduction studies in animals were not adequate to assess [0m
[31mall aspects of fertility. Nevertheless, female rats administered pimozide had prolonged estrus cycles, an effect also produced by other antipsychotic drugs. PREGNANCY Teratogenic Effects: Pregnancy [0m
[31mCategory C. Reproduction studies performed in rats and rabbits at oral doses up to [0m[1;31m8[0m[31m times the maximum human dose did not reveal evidence of teratogenicity. In the rat, however, this multiple of the [0m
[31mhuman dose resulted in decreased pregnancies and in the retarded development of fetuses. These effects are thought to be due to an inhibition or delay in implantation which is also observed in rodents[0m
[31madministered other antipsychotic drugs. In the rabbit, maternal toxicity, mortality, decreased weight gain, and embryotoxicity including increased resorptions were dose-related. PIMOZIDE: precautions:[0m
[31mBecause animal reproduction studies are not always predictive of human response, pimozide should be given to a pregnant woman only if the potential benefits of treatment clearly outweigh the potential[0m
[31mrisks. Nonteratogenic effects. Neonates exposed to antipsychotic drugs, during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery. There have[0m
[31mbeen reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress and feeding disorder in these neonates. These complications have varied in severity; while in some cases [0m
[31msymptoms have been self-limited, in other cases neonates have required intensive care unit support and prolonged hospitalization. Pimozide should be used during pregnancy only if the potential benefit[0m
[31mjustifies the potential risk to the fetus. LABOR & DELIVERY This drug has no recognized use in labor or delivery.         [0m
[31mSOURCE:PIMOZIDE label[0m


[31mCONTENT: PIMOZIDE: drug_interactions: DRUG INTERACTIONS Because pimozide prolongs the QT interval of the electrocardiogram, an additive effect on QT interval would be anticipated if administered with [0m
[31mother drugs, such as phenothiazines, tricyclic antidepressants or antiarrhythmic agents, which prolong the QT interval. Accordingly, pimozide should not be given with dofetilide, sotalol, quinidine, [0m
[31mother Class Ia and III anti-arrhythmics, mesoridazine, thioridazine, chlorpromazine, droperidol, sparfloxacin, gatifloxacin, moxifloxacin, halofantrine, mefloquine, pentamidine, arsenic trioxide, [0m
[31mlevomethadyl acetate, dolasetron mesylate, probucol, tacrolimus, ziprasidone, or other drugs that have demonstrated QT prolongation as one of their pharmacodynamic effects. PIMOZIDE: [0m
[31mdrug_interactions: Also, the use of macrolide antibiotics in patients with prolonged QT intervals has been rarely associated with ventricular arrhythmias. Such concomitant administration should not be[0m
[31mundertaken [0m[1;31m([0m[31msee CONTRAINDICATIONS [0m[1;31m)[0m[31m. Since pimozide is partly metabolized via CYP 3A4, it should not be administered concomitantly with inhibitors of this metabolic system, such as azole antifungal [0m
[31magents and protease inhibitor drugs [0m[1;31m([0m[31msee CONTRAINDICATIONS[0m[1;31m)[0m[31m. Pimozide and Celexa: In a controlled study, a single dose of pimozide [0m[1;31m2[0m[31m mg coadministered with racemic citalopram [0m[1;31m40[0m[31m mg given once daily [0m
[31mfor [0m[1;31m11[0m[31m days was associated with a mean increase in QTc values of approximately [0m[1;31m10[0m[31m msec compared to pimozide given alone. Racemic citalopram did not alter the mean AUC or C max of pimozide. The [0m
[31mmechanism of this pharmacodynamic interaction is not known. PIMOZIDE: drug_interactions: Concomitant use of Pimozide and Celexa or Lexapro is contraindicated [0m[1;31m([0m[31mSee CONTRAINDICATIONS [0m[1;31m)[0m[31m. CYP 2D6 [0m
[31minhibitors: In healthy subjects, co-administration of pimozide [0m[1;31m2[0m[31m mg [0m[1;31m([0m[31msingle dose[0m[1;31m)[0m[31m and paroxetine [0m[1;31m60[0m[31m mg resulted in a [0m[1;31m151[0m[31m% increase in pimozide AUC and a [0m[1;31m62[0m[31m% increase in pimozide C max compared to [0m
[31mpimozide administered alone. The increase in pimozide AUC and C max is related to the CYP 2D6 inhibitory properties of paroxetine. Concomitant use of pimozide and paroxetine or other strong CYP 2D6 [0m
[31minhibitors are contraindicated [0m[1;31m([0m[31msee CONTRAINDICATIONS [0m[1;31m)[0m[31m. PIMOZIDE: drug_interactions: As CYP 1A2 may also contribute to the metabolism of pimozide, prescribers should be aware of the theoretical [0m
[31mpotential for drug interactions with inhibitors of this enzymatic system. Pimozide may be capable of potentiating CNS depressants, including analgesics, sedatives, anxiolytics, and alcohol. Rare case [0m
[31mreports have suggested possible additive effects of pimozide and fluoxetine leading to bradycardia. Concomitant administration of pimozide and sertraline should be contraindicated [0m[1;31m([0m[31mSee [0m
[31mCONTRAINDICATIONS [0m[1;31m)[0m[31m. Pharmacogenomics Individuals with genetic variations resulting in poor CYP 2D6 metabolism [0m[1;31m([0m[31mapproximately [0m[1;31m5[0m[31m to [0m[1;31m10[0m[31m% of the population[0m[1;31m)[0m[31m exhibit higher pimozide concentrations than [0m
[31mextensive CYP 2D6 metabolizers.         [0m
[31mSOURCE:PIMOZIDE label[0m


[31mCONTENT: PIMOZIDE: information_for_patients: INFORMATION FOR PATIENTS Treatment with pimozide tablets, USP exposes the patient to serious risks. A decision to use pimozide tablets, USP chronically in [0m
[31mTouretteâ€™s Disorder is one that deserves full consideration by the patient [0m[1;31m([0m[31mor patientâ€™s family[0m[1;31m)[0m[31m as well as by the treating physician. Because the goal of treatment is symptomatic improvement, the [0m
[31mpatientâ€™s view of the need for treatment and assessment of response are critical in evaluating the impact of therapy and weighing its benefits against the risks. Since the physician is the primary [0m
[31msource of information about the use of a drug in any disease, it is recommended that the following information be discussed with patients and/or their families. Pimozide tablets, USP is intended only [0m
[31mfor use in patients with Touretteâ€™s Disorder whose symptoms are severe and who cannot tolerate, or who do not respond to HALDOL Â® [0m[1;31m([0m[31mhaloperidol[0m[1;31m)[0m[31m. PIMOZIDE: information_for_patients: Given the [0m
[31mlikelihood that a proportion of patients exposed chronically to antipsychotics will develop tardive dyskinesia, it is advised that all patients in whom chronic use is contemplated be given, if [0m
[31mpossible, full information about this risk. The decision to inform patients and/or their guardians must obviously take into account the clinical circumstances and the competency of the patient to [0m
[31munderstand the information provided. There is limited information available on the use of pimozide tablets, USP in children under [0m[1;31m12[0m[31m years of age. The information available on pimozide tablets, USP [0m
[31mfrom foreign marketing experience and from U.S. clinical trials indicates that pimozide tablets, USP has a side effect profile similar to that of other antipsychotic drugs. Patients should be informed[0m
[31mthat all types of side effects associated with the use of antipsychotics may be associated with the use of pimozide tablets, USP. PIMOZIDE: information_for_patients: In addition, sudden, unexpected [0m
[31mdeaths have occurred in patients taking high doses of pimozide tablets, USP for conditions other than Touretteâ€™s Disorder. These deaths may have been the result of an effect of pimozide upon the [0m
[31mheart. Therefore, patients should be instructed not to exceed the prescribed dose of pimozide tablets, USP and they should realize the need for the initial ECG and for follow-up ECGs during treatment.[0m
[31mAlso, pimozide, at a dose about [0m[1;31m15[0m[31m times that given humans, caused an increase in the number of benign tumors of the pituitary gland in female mice. It is not possible to say how important this is. [0m
[31mSimilar tumors were not seen in rats given pimozide, nor at lower doses in mice, which is reassuring. However, any such finding must be considered to suggest a possible risk of long term use of the [0m
[31mdrug. PIMOZIDE: information_for_patients: Because substances in grapefruit juice may inhibit the metabolism of pimozide by CYP 3A4, patients should be advised to avoid grapefruit juice.         [0m
[31mSOURCE:PIMOZIDE label[0m


[31mCONTENT: PIMOZIDE: warnings: [0m[1;31m)[0m[31m Neuroleptic Malignant Syndrome [0m[1;31m([0m[31mNMS[0m[1;31m)[0m[31m A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome [0m[1;31m([0m[31mNMS[0m[1;31m)[0m[31m has been reported in association [0m
[31mwith antipsychotic drugs. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status [0m[1;31m([0m[31mincluding catatonic signs[0m[1;31m)[0m[31m and evidence of autonomic instability [0m[1;31m([0m[31mirregular pulse or [0m
[31mblood pressure, tachycardia, diaphoresis, and cardiac dysrhythmias[0m[1;31m)[0m[31m. Additional signs may include elevated creatine phosphokinase, myoglobinuria [0m[1;31m([0m[31mrhabdomyolysis[0m[1;31m)[0m[31m and acute renal failure. The [0m
[31mdiagnostic evaluation of patients with this syndrome is complicated. In arriving at a diagnosis, it is important to identify cases where the clinical presentation includes both serious medical illness[0m
[1;31m([0m[31me.g., pneumonia, systemic infection, etc.[0m[1;31m)[0m[31m and untreated or inadequately treated extrapyramidal signs and symptoms [0m[1;31m([0m[31mEPS[0m[1;31m)[0m[31m. PIMOZIDE: warnings: Other important considerations in the differential [0m
[31mdiagnosis include central anticholinergic toxicity, heat stroke, drug fever and primary central nervous system [0m[1;31m([0m[31mCNS[0m[1;31m)[0m[31m pathology. The management of NMS should include [0m[1;31m1[0m[1;31m)[0m[31m immediate discontinuation of [0m
[31mantipsychotic drugs and other drugs not essential to concurrent therapy, [0m[1;31m2[0m[1;31m)[0m[31m intensive symptomatic treatment and medical monitoring, and [0m[1;31m3[0m[1;31m)[0m[31m treatment of any concomitant serious medical problems for [0m
[31mwhich specific treatments are available. There is no general agreement about specific pharmacological treatment regimens for uncomplicated NMS. If a patient requires antipsychotic drug treatment after[0m
[31mrecovery from NMS, the potential reintroduction of drug therapy should be carefully considered. The patient should be carefully monitored, since recurrences of NMS have been reported. Hyperpyrexia, [0m
[31mnot associated with the above symptom complex, has been reported with other antipsychotic drugs. Other Sudden, unexpected deaths have occurred in experimental studies of conditions other than [0m
[31mTouretteâ€™s Disorder. PIMOZIDE: warnings: These deaths occurred while patients were receiving dosages in the range of [0m[1;31m1[0m[31m mg per kg. One possible mechanism for such deaths is prolongation of the QT [0m
[31minterval predisposing patients to ventricular arrhythmia. An electrocardiogram should be performed before pimozide treatment is initiated and periodically thereafter, especially during the period of [0m
[31mdose adjustment. Pimozide may have a tumorigenic potential. Based on studies conducted in mice, it is known that pimozide can produce a dose-related increase in pituitary tumors. The full significance[0m
[31mof this finding is not known, but should be taken into consideration in the physicianâ€™s and patientâ€™s decisions to use this drug product. This finding should be given special consideration when the [0m
[31mpatient is young and chronic use of pimozide is anticipated [0m[1;31m([0m[31msee PRECAUTIONS - Carcinogenesis, Mutagenesis, Impairment of Fertility [0m[1;31m)[0m[31m.         [0m
[31mSOURCE:PIMOZIDE label[0m


[31mCONTENT: PIMOZIDE: adverse_reactions: [0m[1;31m7[0m[1;31m)[0m[31m Increased Salivation [0m[1;31m5[0m[31m [0m[1;31m([0m[1;31m13.8[0m[1;31m)[0m[31m [0m[1;31m2[0m[31m [0m[1;31m([0m[1;31m5.5[0m[1;31m)[0m[31m Musculoskeletal Myalgia [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m2.7[0m[1;31m)[0m[31m [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m2.7[0m[1;31m)[0m[31m Central Nervous System Dreaming Abnormal [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m2.7[0m[1;31m)[0m[31m [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m2.7[0m[1;31m)[0m[31m Hyperkinesia [0m[1;31m2[0m[31m [0m[1;31m([0m[1;31m5.5[0m[1;31m)[0m[31m [0m[1;31m1[0m[31m [0m
[1;31m([0m[1;31m2.7[0m[1;31m)[0m[31m Somnolence [0m[1;31m10[0m[31m [0m[1;31m([0m[1;31m27.7[0m[1;31m)[0m[31m [0m[1;31m9[0m[31m [0m[1;31m([0m[1;31m25.0[0m[1;31m)[0m[31m Torticollis [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m2.7[0m[1;31m)[0m[31m [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m2.7[0m[1;31m)[0m[31m Tremor, Limbs [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m2.7[0m[1;31m)[0m[31m [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m2.7[0m[1;31m)[0m[31m Psychiatric Adverse Behavior Effect [0m[1;31m10[0m[31m [0m[1;31m([0m[1;31m27.7[0m[1;31m)[0m[31m [0m[1;31m8[0m[31m [0m[1;31m([0m[1;31m22.2[0m[1;31m)[0m[31m Nervous [0m[1;31m3[0m[31m [0m[1;31m([0m[1;31m8.3[0m[1;31m)[0m[31m [0m[1;31m2[0m[31m [0m[1;31m([0m[1;31m5.5[0m[1;31m)[0m[31m Skin Rash [0m[1;31m3[0m[31m [0m[1;31m([0m[1;31m8.3[0m[1;31m)[0m[31m [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m2.7[0m[1;31m)[0m[31m [0m
[31mSpecial Senses Visual Disturbance [0m[1;31m2[0m[31m [0m[1;31m([0m[1;31m5[0m[31m. PIMOZIDE: adverse_reactions: [0m[1;31m5[0m[1;31m)[0m[31m [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m2.7[0m[1;31m)[0m[31m Cardiovascular ECG Abnormal [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m2.7[0m[1;31m)[0m[31m [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m2.7[0m[1;31m)[0m[31m Because clinical investigational experience with pimozide in Touretteâ€™s [0m
[31mDisorder is limited, uncommon adverse reactions may not have been detected. The physician should consider that other adverse reactions associated with antipsychotics may occur. Other Adverse Reactions[0m
[31mIn addition to the adverse reactions listed above, those listed below have been reported in U.S. clinical trials of pimozide in conditions other than Touretteâ€™s Disorder. PIMOZIDE: adverse_reactions: [0m
[31mBody as a Whole: Asthenia, chest pain, periorbital edema Cardiovascular/Respiratory: Postural hypotension, hypotension, hypertension, tachycardia, palpitations Gastrointestinal: Increased salivation, [0m
[31mnausea, vomiting, anorexia, GI distress Endocrine: Loss of libido Metabolic/Nutritional: Weight gain, weight loss Central Nervous System: Dizziness, tremor, parkinsonism, fainting, dyskinesia [0m
[31mPsychiatric: Excitement Skin: Rash, sweating, skin irritation Special Senses: Blurred vision, cataracts Urogenital: Nocturia, urinary frequency Postmarketing Reports The following experiences were [0m
[31mdescribed in spontaneous postmarketing reports. These reports do not provide sufficient information to establish a clear causal relationship with the use of pimozide. PIMOZIDE: adverse_reactions: [0m
[31mGastrointestinal: Gingival hyperplasia in one patient Hematologic: Hemolytic anemia Metabolic/Nutritional: Hyponatremia Other: Seizure         [0m
[31mSOURCE:PIMOZIDE label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: The provided extracts from the PIMOZIDE label do not specifically mention an increase or decrease in the risk of myocardial infarction. However, it is noted that pimozide can prolong the QT [0m
[32minterval of the electrocardiogram, which could predispose patients to ventricular arrhythmia, a condition that can be related to myocardial infarction. Patients are advised to have an [0m
[32melectrocardiogram performed before initiating pimozide treatment and periodically thereafter, especially during the period of dose adjustment.[0m

[32mSOURCE: PIMOZIDE label[0m
[32mEXTRACT_START_END: Because pimozide prolongs the QT interval[0m[32m...[0m[32m predisposing patients to ventricular arrhythmia.[0m
*[1m([0morchestrator-myocardial infarction-PIMOZIDE[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: The provided extracts from the PIMOZIDE label do not [0m
[34mspecifically mention an increase or decrease in the risk of myocardial infarction. However, it is noted that pimozide can prolong the QT interval of the electrocardiogram, which could predispose [0m
[34mpatients to ventricular arrhythmia, a condition that can be related to myocardial infarction. Patients are advised to have an electrocardiogram performed before initiating pimozide treatment and [0m
[34mperiodically thereafter, especially during the period of dose adjustment.[0m

[34mSOURCE: PIMOZIDE label[0m
[34mEXTRACT_START_END: Because pimozide prolongs the QT interval[0m[34m...[0m[34m predisposing patients to ventricular arrhythmia.[0m
 [1m([0morchestrator-myocardial infarction-PIMOZIDE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-myocardial infarction-PIMOZIDE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-myocardial infarction-PIMOZIDE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does PIMOZIDE increase or decrease the risk of myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler if PIMOZIDE increases or decreases the risk of myocardial infarction."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that the PIMOZIDE label does not specifically mention an increase or decrease in the risk of myocardial infarction."[0m[32m,[0m
[32m      [0m[32m"However, FDAHandler noted that PIMOZIDE can prolong the QT interval, which could predispose patients to ventricular arrhythmia, a condition that can be related to myocardial infarction."[0m[32m,[0m
[32m      [0m[32m"Patients are advised to have an electrocardiogram performed before initiating PIMOZIDE treatment and periodically thereafter, especially during the period of dose adjustment."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"The FDA label for PIMOZIDE does not specifically mention an increase or decrease in the risk of myocardial infarction. However, it does note that PIMOZIDE can prolong the QT interval, [0m
[32mwhich could predispose patients to ventricular arrhythmia, a condition that can be related to myocardial infarction. Therefore, while there is a potential risk factor related to heart health, the [0m
[32mdirect effect on myocardial infarction risk is not explicitly stated in the FDA label."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-myocardial infarction-PIMOZIDE[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-myocardial infarction-PIMOZIDE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-myocardial infarction-PIMOZIDE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-myocardial infarction-PIMOZIDE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does PIMOZIDE increase or decrease the risk of myocardial infarction?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler if PIMOZIDE increases or decreases the risk of myocardial infarction."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that the PIMOZIDE label does not specifically mention an increase or decrease in the risk of myocardial infarction."[0m[34m,[0m
[34m      [0m[34m"However, FDAHandler noted that PIMOZIDE can prolong the QT interval, which could predispose patients to ventricular arrhythmia, a condition that can be related to myocardial infarction."[0m[34m,[0m
[34m      [0m[34m"Patients are advised to have an electrocardiogram performed before initiating PIMOZIDE treatment and periodically thereafter, especially during the period of dose adjustment."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"The FDA label for PIMOZIDE does not specifically mention an increase or decrease in the risk of myocardial infarction. However, it does note that PIMOZIDE can prolong the QT interval, [0m
[34mwhich could predispose patients to ventricular arrhythmia, a condition that can be related to myocardial infarction. Therefore, while there is a potential risk factor related to heart health, the [0m
[34mdirect effect on myocardial infarction risk is not explicitly stated in the FDA label."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does PIMOZIDE increase or decrease the risk of myocardial infarction?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler if PIMOZIDE increases or decreases the risk of myocardial infarction.[0m
[1;31m2[0m[31m. FDAHandler responded that the PIMOZIDE label does not specifically mention an increase or decrease in the risk of myocardial infarction.[0m
[1;31m3[0m[31m. However, FDAHandler noted that PIMOZIDE can prolong the QT interval, which could predispose patients to ventricular arrhythmia, a condition that can be related to myocardial infarction.[0m
[1;31m4[0m[31m. Patients are advised to have an electrocardiogram performed before initiating PIMOZIDE treatment and periodically thereafter, especially during the period of dose adjustment.[0m
[31m        -----[0m
[31m        Final answer: The FDA label for PIMOZIDE does not specifically mention an increase or decrease in the risk of myocardial infarction. However, it does note that PIMOZIDE can prolong the QT [0m
[31minterval, which could predispose patients to ventricular arrhythmia, a condition that can be related to myocardial infarction. Therefore, while there is a potential risk factor related to heart [0m
[31mhealth, the direct effect on myocardial infarction risk is not explicitly stated in the FDA label.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-myocardial infarction-PIMOZIDE[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-myocardial infarction-PIMOZIDE[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-myocardial infarction-PIMOZIDE[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-myocardial infarction-PIMOZIDE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-myocardial infarction-PIMOZIDE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mThe FDA label for PIMOZIDE does not specifically mention an increase or decrease in the risk of myocardial infarction. However, it does note that PIMOZIDE can prolong the QT interval, which could [0m
[32mpredispose patients to ventricular arrhythmia, a condition that can be related to myocardial infarction. Therefore, while there is a potential risk factor related to heart health, the direct effect on[0m
[32mmyocardial infarction risk is not explicitly stated in the FDA label.[0m
